NTIDs with high variability [Design Issues]

posted by ioanam – Romania, 2010-06-07 15:52 (5494 d 04:10 ago) – Posting: # 5452
Views: 10,441

Which is the most appropriate design for a narrow therapeutic index drug with very high intra-subject variability?

For example, we have an immunosuppressive agent with an intra-subject CV% > 45%.
Using a standard two – way crossover design with acceptance interval tightened (90.00 – 111.11%), we will have a sample size of more than 300 subjects :-(.

It is possible to use a replicate design in this situation?

Thank you,
Jo

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
50 visitors (0 registered, 50 guests [including 12 identified bots]).
Forum time: 20:03 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5